MAI Capital Management Grows Stake in Gilead Sciences, Inc. $GILD

MAI Capital Management grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 47.6% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 42,314 shares of the biopharmaceutical company’s stock after purchasing an additional 13,649 shares during the quarter. MAI Capital Management’s holdings in Gilead Sciences were worth $4,697,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Norges Bank bought a new position in Gilead Sciences during the 2nd quarter worth about $2,150,268,000. Ameriprise Financial Inc. lifted its position in shares of Gilead Sciences by 397.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after purchasing an additional 5,392,191 shares during the period. Invesco Ltd. lifted its position in shares of Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after purchasing an additional 3,394,330 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of Gilead Sciences by 164.4% during the third quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock valued at $387,286,000 after purchasing an additional 2,169,266 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Gilead Sciences by 1.6% during the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after buying an additional 1,893,401 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00. Following the transaction, the chief executive officer owned 613,912 shares in the company, valued at approximately $92,086,800. This represents a 15.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 299,280 shares of company stock worth $42,487,570 in the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. HSBC upped their target price on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday, December 10th. Royal Bank Of Canada lifted their target price on Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 11th. Wells Fargo & Company increased their price target on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Truist Financial raised their price target on shares of Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Finally, Citigroup boosted their price objective on shares of Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a research note on Tuesday, January 27th. Twenty-three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $156.72.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Daiwa Securities raised its price target on GILD to $161 and kept an “outperform” rating — a signal that some sell‑side desks see ~double‑digit upside from current levels. Daiwa Securities adjusts price target on Gilead Sciences to $161 from $129; maintains outperform
• Positive Sentiment: Zacks Research raised multiple quarterly and multi‑year EPS estimates (FY2026–FY2028), reflecting better near‑term earnings visibility and supporting consensus upward revisions for 2026–2027 (Zacks now modeling higher EPS across several quarters).
• Positive Sentiment: UBS reiterated a Buy and kept a $175 price target, citing Gilead’s advancing long‑acting HIV franchise as a durable competitive advantage for future revenue growth. Gilead Sciences: Advancing Long-Acting HIV Franchise Underscores Competitive Edge and Supports Buy Rating
• Positive Sentiment: New Phase 3 ARTISTRY data presented at CROI show Gilead’s investigational single‑tablet bictegravir/lenacapavir maintained virological suppression with low discontinuation—strengthening Gilead’s HIV pipeline narrative and potential product breadth. Gilead’s Single-Tablet Regimen Maintained Virological Suppression (Business Wire)
• Neutral Sentiment: Gilead agreed to acquire Arcellx for $115/share (~$7.8B) to bolster its oncology/BCMA pipeline — strategic for growth but sizable; market reaction can be mixed while investors assess synergies, price and integration. Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy
• Negative Sentiment: Competitive pressure: Merck’s two‑drug HIV regimen matched Gilead’s Biktarvy in Phase 3 and is under FDA review — a meaningful competitor that raises pricing and market‑share concerns in the core HIV franchise. Merck’s New HIV Drug Shows Promise (Yahoo Finance)
• Negative Sentiment: Large M&A and ongoing competition increase near‑term uncertainty (integration costs, potential dilution, and execution risk), which can pressure the stock despite positive fundamental news.

Gilead Sciences Stock Down 2.3%

GILD stock opened at $143.77 on Friday. The stock has a market capitalization of $178.48 billion, a PE ratio of 21.24, a price-to-earnings-growth ratio of 1.93 and a beta of 0.36. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29. The company has a quick ratio of 1.31, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The firm has a 50 day moving average of $135.61 and a 200 day moving average of $124.58.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the company posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a $0.82 dividend. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. Gilead Sciences’s dividend payout ratio (DPR) is 46.68%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.